Pneumonia mapped in largest genomic survey of any disease-causing bacterium
Researchers have mapped the most common bacterial cause of pneumonia around the world and revealed how these bacteria evolve in response to vaccination. Scientists from the Wellcome Sanger Institute, Emory University (Atlanta, USA), and the U.S. Centers for Disease Control and Prevention worked with many collaborators around the world to carry out a global genomic survey of Streptococcus pneumoniae, discovering 621 strains across more than fifty countries.
The research is published in The Lancet Infectious Diseases today (10th June), and with a sister paper in EBioMedicine, reveals which strains of S. pneumoniae (also known as the pneumococcus) are circulating around the world and explains why pneumococcal pneumonia rates are still high despite the existing vaccines. Funded by a grant from the Bill & Melinda Gates Foundation, this work will help predict which strains will be important for new pneumococcal vaccines, and shows that ongoing global genomic surveillance is vital.
Pneumonia is an infection of the lungs that is responsible for the deaths of hundreds of thousands of people a year globally and is the single largest infectious cause of death of children under 5 years old worldwide. Streptococcus pneumoniae is the most common cause of bacterial pneumonia. Healthy people often carry these bacteria without becoming ill, but they can cause fatal infection, especially in young children and some adults.
Many countries around the world have introduced the pneumococcal conjugate vaccine (PCV) over the last ten years. This vaccine, which targets the coat around each S. pneumoniae bacterium, has greatly reduced the number of childhood infections. However, while PCV is highly effective against up to 13 important coat types, there are over a hundred types known, and despite the vaccine, pneumococcal pneumonia rates remain very high.
To understand and help combat this infection, researchers set up the Global Pneumococcal Sequencing project (GPS) to carry out genomic surveillance of S. pneumoniae worldwide. Working with partners around the world, the researchers sequenced the DNA of over 20,000 S. pneumoniae samples from infected people from 51 countries.
Samples were collected both before and after PCV introduction, and the DNA sequences and health data were compared. This makes it possible to determine changes in the bacteria that could affect how well the vaccine protects against the pneumococcus, and whether new strains are emerging that would impact disease severity and ease of treatment.
The researchers discovered 621 genetic strains globally, each associated with one or more coat types. They also saw that the levels of non-vaccine type bacteria rose after the introduction of PCV, showing how bacteria evolve in response to the vaccine.
Professor Stephen Bentley, senior author on the papers, from the Wellcome Sanger Institute, said: "Pneumonia is a huge threat to health worldwide. We now have an unprecedented view of the global population of S. pneumoniae bacteria, the usual cause of bacterial pneumonia, and can see evolutionary changes that lead to vaccine evasion. This will give crucial information for future vaccine strategy worldwide, and help save lives."
Dr. Rebecca Gladstone, joint first author on two of the papers, from the Wellcome Sanger Institute, said: "Our study gives the first genomic description of the S. pneumoniae population of the world. This has never been possible before, as previously only samples from individual populations had been studied. Now we have global data, showing which strains are present in each country, and can use this to understand pneumococcal infection on a world-wide scale."
The pneumococcus can cause disease in other areas of the body too, for example infecting the brain or blood, causing meningitis or bloodstream infections, which can all lead to sepsis. Infant vaccination with PCV protects against these pneumococcal infections too. By reducing the transmission of S. pneumoniae between children, PCV also reduces the number of adult infections through herd immunity.
Dr. Lesley McGee, Co-Principal Investigator on the project from the Streptococcus Laboratory at the Centers for Disease Control and Prevention in the United States, said: "It is vital to understand the strains of S. pneumoniae present around the world, and how they respond to the introduction of PCV. This genomic study allows us to not only see the current most important global strains but also helps understand their evolution. This information will open the door to developing predictive tools to identify the strains likely to emerge in response to vaccine use."
Professor Robert Breiman, Director of the Emory Global Health Institute, and Principal Investigator for the project, added: "GPS turns a spotlight onto a new era in which the intersection of genomics and public health enables unparalleled capacity for optimizing prevention strategies, while providing an immensely valuable tool for forecasting and addressing new challenges ahead."
Professor Keith Klugman, Director of the Pneumonia team at the Bill & Melinda Gates Foundation, said: "We must continue to immunize children around the world because vaccination is the single best way of reducing the risk of pneumonia, as it prevents children passing S. pneumoniae between them and adults. However, we are fighting a battle against evolution of bacterial strains. This research shows the importance of ongoing global genomic surveillance to understand which strains are likely to cause a threat, to help reformulate the next generation of vaccines."
More information: Stephanie W Lo et al, Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study, The Lancet Infectious Diseases (2019). DOI: 10.1016/S1473-3099(19)30297-X